NCT00928642View on ClinicalTrials.gov

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Ovarian CancerPrimary Peritoneal Cancer
Interventions
DRUG

imatinib mesylate by mouth

imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.

DRUG

Gemcitabine Intravenous

Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle

Trial Locations (1)

98431

Madigan Army Medical Center, Tacoma

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

NCT00928642 - Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter